Why MLYS? Mineralys Therapeutics, Inc. Analysis, Price & AI Insights | Whystock
MLYS
$29.26+2.61 (+9.79%)
Market ClosedLast close May 1
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.